CN1867358A - 用于治疗抑郁症的5－羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物 - Google Patents

用于治疗抑郁症的5－羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物 Download PDF

Info

Publication number
CN1867358A
CN1867358A CNA2004800304533A CN200480030453A CN1867358A CN 1867358 A CN1867358 A CN 1867358A CN A2004800304533 A CNA2004800304533 A CN A2004800304533A CN 200480030453 A CN200480030453 A CN 200480030453A CN 1867358 A CN1867358 A CN 1867358A
Authority
CN
China
Prior art keywords
phenyl
propyl
methyl
chloro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800304533A
Other languages
English (en)
Chinese (zh)
Inventor
M·迪德里克森
S·霍格维利格尔斯
J·阿恩特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1867358A publication Critical patent/CN1867358A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2004800304533A 2003-08-21 2004-08-18 用于治疗抑郁症的5－羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物 Pending CN1867358A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49673803P 2003-08-21 2003-08-21
DKPA200301198 2003-08-21
DKPA200301198 2003-08-21

Publications (1)

Publication Number Publication Date
CN1867358A true CN1867358A (zh) 2006-11-22

Family

ID=34219531

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800304533A Pending CN1867358A (zh) 2003-08-21 2004-08-18 用于治疗抑郁症的5－羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物

Country Status (12)

Country Link
US (1) US20060223857A1 (enExample)
EP (1) EP1660130A1 (enExample)
JP (1) JP2007502785A (enExample)
KR (1) KR20060066729A (enExample)
CN (1) CN1867358A (enExample)
AU (1) AU2004266057A1 (enExample)
BR (1) BRPI0413587A (enExample)
CA (1) CA2536275A1 (enExample)
IS (1) IS8277A (enExample)
MX (1) MXPA06002002A (enExample)
NO (1) NO20061167L (enExample)
WO (1) WO2005018676A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005989A (es) * 2001-12-20 2004-09-27 Lundbeck & Co As H Derivados de ariloxifenilo y arilsulfanilfenilo.
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
NZ332780A (en) * 1996-05-31 2000-07-28 Allelix Neuroscience Inc Substituted amines for the treatment of neurological and neuropsychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
WO2002008216A1 (en) * 2000-07-21 2002-01-31 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
MXPA04005989A (es) * 2001-12-20 2004-09-27 Lundbeck & Co As H Derivados de ariloxifenilo y arilsulfanilfenilo.
DE60312874T2 (de) * 2002-06-20 2008-01-17 H. Lundbeck A/S Kombinationstherapie mit verwendung eines serotonin-wiederaufnahmehemmers
CN1794981A (zh) * 2003-05-27 2006-06-28 森林实验室公司 治疗抑郁症和其它情绪障碍的nmda受体拮抗剂和选择性5－羟色胺重摄取抑制剂的组合

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒

Also Published As

Publication number Publication date
NO20061167L (no) 2006-03-13
EP1660130A1 (en) 2006-05-31
WO2005018676A1 (en) 2005-03-03
MXPA06002002A (es) 2006-05-17
BRPI0413587A (pt) 2006-10-17
CA2536275A1 (en) 2005-03-03
US20060223857A1 (en) 2006-10-05
AU2004266057A1 (en) 2005-03-03
IS8277A (is) 2006-01-31
JP2007502785A (ja) 2007-02-15
KR20060066729A (ko) 2006-06-16

Similar Documents

Publication Publication Date Title
US20100267772A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
CN101065014A (zh) 通过诱导逆适应调节神经递质系统的方法
JP2007508236A (ja) うつ病およびその他の情動障害を治療する方法
CN1662246A (zh) 使用5－羟色胺再摄取抑制剂的联合疗法
CN1867358A (zh) 用于治疗抑郁症的5－羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物
CN1893935A (zh) 一种5－羟色胺再吸收抑制剂与一种组胺3受体拮抗剂、逆激动剂或部分激动剂的组合
JP2007513896A6 (ja) セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
AU2004296531A1 (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
HK1098694A (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
JP2007504181A (ja) セロトニン再取り込み阻害剤およびロキサピンの併用
CN1845730A (zh) 5－羟色胺再摄取抑制剂与克塞平的组合
CN1809350A (zh) 抑郁症和其他情感障碍的治疗
HK1082681A (en) Combination therapy wherein a serotonin reuptake inhibitor is used
HK1102557A (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US20080167290A1 (en) Combination of a Serotonin Reuptake Inhibitor and Amoxapine
MXPA06005127A (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
CN1845744A (zh) 5－羟色胺再摄取抑制剂和阿莫沙平的联合
CA2579520A1 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
HK1092058A (en) Treatment of depression and other affective disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098694

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061122

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1098694

Country of ref document: HK